This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
UnitedHealth Group, Inc. is the largest health care services company in the world, serving over 50 million individuals in the United States as of 2019 and over 5 million internationally. The company provides a wide range of health care products and services, such as health maintenance organizations (HMOs), point of service plans (POS), preferred provider organizations (PPOs), and managed fee-for-service programs. UnitedHealth has the largest and most diverse membership base within the managed-care organization market, which gives it significant competitive advantages. It also has built its prescription drug business through OptumRx division, with the acquisition of Catamaran in 2015.
UnitedHealth Group (UNH) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
UnitedHealth Group (UNH) closed the most recent trading day at $497.10, moving +1.41% from the previous trading session.
Here's Why Investors Should Retain Globus Medical (GMED) Now
by Zacks Equity Research
Globus Medical's (GMED) strong international growth and meaningful product launches raise investors' optimism.
Neogen (NEOG) to Offer New Biosecurity Solution in Canada
by Zacks Equity Research
Neogen's (NEOG) newest addition to the biosecurity portfolio is anticipated to curb the spread of diseases like COVID-19 and avian influenza.
Anthem (ANTM) Up 27% in a Year: Can It Retain the Momentum?
by Zacks Equity Research
Anthem (ANTM) is well-poised for growth on sustained top-line improvement, membership increases in Government business and sturdy financial position.
Tandem Diabetes (TNDM) Posts Positive Control-IQ Study Data
by Zacks Equity Research
Data presented at the ADA conference demonstrates Tandem Diabetes' (TNDM) Control-IQ technology's ability to make a positive and sustained impact across a diverse group of people with diabetes.
Here's Why You Should Hold on to NuVasive (NUVA) Stock for Now
by Zacks Equity Research
Investors are optimistic about NuVasive (NUVA) on strong sales performance across the U.S. spinal hardware and the U.S. surgical support product lines.
HealthEquity (HQY) Q1 Earnings Lag Estimates, FY23 View Up
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust segmental revenues, in the first quarter of fiscal 2023.
Insulet (PODD) Reports Pivotal Extended Phase Data for Omnipod 5
by Zacks Equity Research
Insulet's (PODD) Omnipod 5 showed improved time in range and lower HbA1c for pre-school children during an extended phase of the previous pivotal trial.
Bio-Rad (BIO) Immunohematology Arm Recovers, New Launches Aid
by Zacks Equity Research
Bio-Rad's (BIO) qPCR business is experiencing excellent uptake from the new-generation CFX Opus platform.
Boston Scientific (BSX) Gains from New Buyouts, FX Issue Ails
by Zacks Equity Research
Boston Scientific (BSX) is currently looking forward to launching its arterial and venous offerings in the second half of 2022.
Abbott (ABT) FreeStyle Libre 3 System's Study Outcome Favorable
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre 3 system is the first and only 14-day CGM system with an overall MARD of 7.9%.
Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) on a strong recovery in the base business and the raised 2022 outlook.
LabCorp (LH) to Enhance Access to OmniSeq INSIGHT via New Program
by Zacks Equity Research
LabCorp's (LH) new sponsored lung cancer program will expand access to comprehensive genomic testing for NSCLC patients to guide informed treatment decisions.
Zacks Industry Outlook Highlights UnitedHealth Group Anthem, Humana, Centene, and Select Medical
by Zacks Equity Research
UnitedHealth Group, Anthem, Humana, Centene, and Select Medical are part of Zacks Industry Outlook article.
Here's Why You Should Retain Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors are optimistic about Bruker (BRKR) on strength across the BSI and BEST businesses.
Phibro (PAHC) Business Hurt by Macro Issues, FX Fluctuations
by Zacks Equity Research
The increase in raw material costs and freight costs continues to pose challenges for Phibro (PAHC).
Here's Why Investors Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell's (OMCL) better-than-expected results and new launches.
Veeva Systems (VEEV) Beats on Q1 Earnings, Ups FY23 View
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performances by both of its segments.
The Zacks Analyst Blog Highlights 3M, Cigna, UnitedHealth Group, Exxon Mobil, and ConocoPhillips
by Zacks Equity Research
3M, Cigna, UnitedHealth Group, Exxon Mobil, and ConocoPhillips are part of Zacks top Analyst Blog
NEOGEN (NEOG) Launches Insecticide for Poultry Producers
by Zacks Equity Research
NEOGEN's (NEOG) insect control solution for poultry producers is the latest addition to the company's Prozap product line.
5 HMO Stocks Set to Gain From Membership Growth, M&A Strategy
by Debasmita Chatterjee
Rising membership and a rapidly growing aging U.S. population are likely to drive the performances of the Zacks Medical-HMO industry players. UNH, ANTM, HUM, CNC and SEM are poised to benefit from improved operational efficiencies.
Insulet (PODD) to Expand Base in Malaysia With New Facility
by Zacks Equity Research
The new manufacturing facility by Insulet (PODD) is set to have approximately 400,000 square feet of manufacturing space.
UnitedHealth Group (UNH) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
UnitedHealth Group (UNH) closed at $492.55 in the latest trading session, marking a -0.85% move from the prior day.
Here's Why You Should Retain Thermo Fisher (TMO) for Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher's (TMO) robust y/y revenue growth in the Analytical Instruments, and the Laboratory Products and Biopharma Services segments.
Illumina's (ILMN) GRAIL to Assess Galleri Test With New Deal
by Zacks Equity Research
Illumina (ILMN) GRAIL's recent collaboration is part of REFLECTION, a real-world observational study assessing the performance of the Galleri MCED test in clinical settings.